Elix's AI Revolutionizes Drug Discovery with KYORIN, Tempus Acquires Paige for $81.25M - Life AI Weekly #31

Hi there,

In this week's edition of Life AI Weekly, we're diving into the latest advancements in AI within the healthcare and life sciences sectors. Elix's AI Platform has been adopted by KYORIN Pharmaceutical, marking a significant step in AI-driven drug discovery. Meanwhile, Ginkgo Bioworks, Tangible Scientific, and Inductive Bio have teamed up to enhance biopharma research through AI collaboration.

On the healthcare technology front, Ant Group and Peking University Hospital have launched a new AI lab, aiming to revolutionize medical research and patient care. Additionally, Mount Sinai has developed an AI tool for analyzing cancer tissue, potentially improving diagnostic accuracy and treatment outcomes. Stay tuned as we explore these stories and more in this edition.

Twin Health has secured $53 million to advance its AI digital twin technology, aiming to improve diabetes and obesity treatment. Meanwhile, Tempus has acquired Paige for $81.25 million, enhancing its precision medicine capabilities with Paige's digital pathology expertise.

Life AI Weekly explores the latest advancements in AI across various sectors. This week, we delve into groundbreaking developments in drug discovery, research, biotech, business, and healthcare tech, highlighting key innovations and strategic appointments shaping the future of AI.

Life AI Weekly brings you the latest in AI advancements and applications. This week, we delve into the transformative impact of AI in various sectors, highlighting key developments and innovations.

Citius Oncology, Inc. has launched an AI platform to enhance its commercial team's capabilities ahead of the LYMPHIR™ therapy release for cutaneous T-cell lymphoma. Meanwhile, PayerWatch has introduced AI-assisted appeal drafting in its Veracity™ platform, achieving a 96% accuracy rate on Emergency Department Level-of-Care downgrades.